Voyager therapeutics, inc. (VYGR)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flow from operating activities
Net loss

-40,690

-43,597

-53,554

-58,837

-95,532

-88,288

-77,586

-80,643

-73,976

-70,698

-73,542

-59,193

-49,653

-40,193

-32,803

-27,723

-22,283

-29,672

0

0

0

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Stock-based compensation expense

16,162

15,640

14,758

14,045

16,906

15,710

15,365

15,970

9,395

9,238

8,727

7,275

7,053

6,310

6,494

5,562

5,147

4,027

0

0

0

Depreciation

3,026

2,800

2,569

2,420

2,260

2,100

1,979

1,846

1,739

1,600

1,323

1,050

793

612

612

612

605

600

0

0

0

Amortization of premiums and discounts on marketable securities

3,218

3,584

3,527

3,099

2,408

2,163

1,784

1,101

425

24

-322

-438

-557

-696

0

0

0

-

-

-

-

Change in fair value of preferred stock tranche liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,750

0

0

0

In-kind research and development expenses

-

616

616

616

392

176

176

176

245

113

0

0

0

-

-

-

-

2,316

0

0

0

Other non-cash items

-161

1,612

1,448

328

-485

-859

-404

-545

1,400

-46

-1,257

-490

-1,527

-709

891

336

307

277

0

0

0

Changes in operating assets and liabilities:
Related party collaboration receivable

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-1,613

-1,675

3,758

-413

4,235

3,937

261

719

-977

-1,630

-1,228

-45

-260

847

302

-451

-111

234

0

0

0

Operating lease, right-of-use asset

-3,015

-2,951

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncurrent assets

0

-

-

-

-

-

-

-

-

-

-

-

1,540

-7

-85

898

-20

-14

0

0

0

Accounts payable

2,120

2,598

2,304

372

589

-282

511

1,251

542

470

124

-147

-867

-62

246

-943

118

-942

0

0

0

Accrued expenses

7,682

11,728

7,950

4,288

52

-1,600

-2,356

258

3,172

4,900

4,285

1,748

2,901

2,636

3,137

3,596

1,837

2,788

0

0

0

Operating lease liabilities

-2,674

-2,506

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-current liabilities

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-189

0

0

0

Lease incentive benefit

-

-

-

-

-

-

-

-

-

-515

0

0

0

-

-

-

-

-

0

0

0

Deferred revenue

-76,123

80,831

95,965

101,963

141,934

61,380

57,043

57,989

59,386

-10,135

-6,153

-8,674

-11,697

-14,582

-17,157

-18,425

-19,108

52,666

0

0

0

Net cash (used in) provided by operating activities

-105,294

48,666

47,678

51,610

60,665

-15,887

-6,373

-4,613

1,554

-61,350

-59,608

-53,910

-47,289

-42,482

-38,947

-35,508

-32,776

41,299

0

0

0

Cash flow from investing activities
Purchases of property and equipment

8,121

7,718

4,865

4,540

3,802

4,305

3,943

3,506

2,647

3,985

7,693

7,784

7,514

5,029

1,281

1,037

1,340

1,030

0

0

0

Proceeds from sale of equipment

-

172

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Purchases of marketable securities

-

494,231

467,915

442,543

538,216

333,228

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

442,500

411,300

384,300

334,800

373,300

364,000

313,500

292,000

194,000

147,600

145,500

159,700

175,700

165,100

0

0

0

-

-

-

-

Net cash provided by (used in) investing activities

155,177

-90,477

-88,309

-112,112

-168,596

26,467

-62,264

-63,839

34,066

-3,681

42,699

52,078

56,307

47,721

-38,135

-55,259

-182,550

-194,769

0

0

0

Cash flow from financing activities
Proceeds from the exercise of stock options

2,464

2,714

3,023

2,359

2,762

3,889

3,179

2,791

2,172

1,363

0

0

0

-

-

-

-

-

-

-

-

Proceeds from the issuance of common stock in connection with the Neurocrine Collaboration Agreement

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the purchase of common stock under ESPP

-

-

-

-

-

860

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of Series A redeemable convertible preferred stock and tranche rights, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Deferred initial public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net cash provided by financing activities

3,127

80,994

81,129

80,773

80,821

4,749

62,578

61,766

61,147

59,920

2,024

1,521

1,112

514

74,056

73,051

132,807

177,744

0

0

0

Net increase in cash and cash equivalents

53,010

39,183

40,498

20,271

-27,110

15,329

-6,059

-6,686

96,767

-5,111

-14,885

-311

10,130

5,753

-3,026

-17,716

-82,519

24,274

0

0

0

Supplemental disclosure of cash and non-cash activities
Impact of adopting new accounting standards

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Capital expenditures incurred but not yet paid

490

434

0

0

0

-

-

-

0

-

-

0

0

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,373

0

0

0